Trial reportJournal of virology2020
Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.
Trial report in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 24 citations in OpenAlex.
- Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection.The Journal of clinical investigation · 2022Trial
- A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination.Cell reports. Medicine · 2021Trial
- Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency.Journal of virology · 2020Trial
- Current Approaches for Assessments of Neutralizing, Binding, and Effector Functions of Antibodies on the Path to Antibody-Mediated Prevention Strategies for HIV-1.Current HIV research · 2026Review
- Activation of CXCR3Journal of virology · 2025Article
- Article
- Increased Chemokine Production is a Hallmark of Rhesus Macaque Natural Killer Cells Mediating Robust Anti-HIV Envelope-Specific Antibody-Dependent Cell-Mediated Cytotoxicity.Pathogens & immunity · 2024Article
- Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.PLoS pathogens · 2023Article
- Multivariate analysis of FcR-mediated NK cell functions identifies unique clustering among humans and rhesus macaques.Frontiers in immunology · 2023Article
- Fc receptors and the diversity of antibody responses to HIV infection and vaccination.Genes and immunity · 2022Review
- Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4Journal of virology · 2022Article
- HIV and SARS-CoV-2: Tracing a Path of Vaccine Research and Development.Current HIV/AIDS reports · 2022Review
- Selection of HIV Envelope Strains for Standardized Assessments of Vaccine-Elicited Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies.Journal of virology · 2022Article
- ADCC-mediating non-neutralizing antibodies can exert immune pressure in early HIV-1 infection.PLoS pathogens · 2021Article
- Article
- Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells.Cell reports · 2021Article
- Structure and Fc-Effector Function of Rhesusized Variants of Human Anti-HIV-1 IgG1s.Frontiers in immunology · 2021Article
- Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodies.The Journal of clinical investigation · 2020Article
- Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice.Microorganisms · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 11 institutions in 2 countries.
Funding
Abstract
Induction of protective antibodies is a critical goal of HIV-1 vaccine development. One strategy is to induce nonneutralizing antibodies (NNAbs) that kill virus-infected cells, as these antibody specificities have been implicated in slowing HIV-1 disease progression and in protection. HIV-1 Env constant region 1 and 2 (C1C2) monoclonal antibodies (MAbs) frequently mediate potent antibody-dependent cellular cytotoxicity (ADCC), making them an important vaccine target. Here, we explore the effect of delayed and repetitive boosting of RV144 vaccine recipients with AIDSVAX B/E on the C1C2-specific MAb repertoire. It was found that boosting increased clonal lineage-specific ADCC breadth and potency. A ligand crystal structure of a vaccine-induced broad and potent ADCC-mediating C1C2-specific MAb showed that it bound a highly conserved Env gp120 epitope. Thus, boosting to affinity mature these types of IgG C1C2-specific antibody responses may be one method by which to make an improved HIV vaccine with higher efficacy than that seen in the RV144 trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.